SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the Month of April 2005
BioProgress PLC
(Translation of registrant’s name into English)
Hostmoor Avenue
March, Cambridgeshire
United Kingdom. PE15 0AX
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No þ
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):N/A
BioProgress PLC
Form 6-K for the month of April, 2005.
Contents:
Enclosure 1.Press release re: Trading update, dated April 13, 2005.
Enclosure 1.
BioProgress PLC
13 April 2005
| | |
| Press Release | | 13 April 2005 |
BioProgress plc
(‘BioProgress’ or ‘the Company’)
Trading update
BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery mechanisms for the pharmaceutical oral dosage markets, advises that current trading levels at its BioTec Films subsidiary in Tampa are not as strong as previously anticipated and are unlikely to reach levels indicated in previous announcements. The Company’s consolidated overheads, before any capital expenditure, are also expected to be higher than previously indicated. The Board retains its belief that, within the Company’s portfolio, there are technologies which could produce significant value on commercialisation. A thorough strategic and financial review is being performed, which the Board will report on in due course.
- Ends -
Forward-Looking Information.
The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. This announcement contains certain ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results. Detailed information about factors pertinent to the business of the Company that could cause actual results to differ is set forth in the Company’s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of this announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.
| | |
| For further information: | | |
| |
| BioProgress plc | | Tel: +44 (0) 7940 913233 |
| Dan Farrow | | |
| dan.farrow@bioprogress.com | | |
| www.bioprogress.com | | |
| |
| UK Media enquiries: | | |
| Abchurch | | |
| Chris Munden / Julian Bosdet | | Tel: +44 (0) 207 398 7700 |
| chris.munden@abchurch-group.com | | |
| www.abchurch-group.com | | |
| |
| US Investor enquiries: | | |
| Taylor Rafferty | | |
| Andrew Saunders | | Tel: +1 212 889 4350 |
| andrew.saunders@taylor-rafferty.com | | |
| www.taylor-rafferty.com | | |
Notes to editors:
BioProgress listed on AIM in May 2003 and on NASDAQ in October 2004, and is engaged in the research, development, and design of patented encapsulation systems that use water soluble and biodegradable films for the dietary supplement, pharmaceutical and other sectors. The Company’s portfolio comprises over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. BioProgress aims to provide a cost effective and animal-free encapsulation process for pharmaceutical drugs in liquids, tablets and powders, thereby addressing the needs of the entire market for oral dosage forms while providing novel delivery mechanisms not possible with traditional processes.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
| | | BIOPROGRESS PLC |
| |
| | | /s/ ELIZABETH EDWARDS
|
Dated: April 13, 2005 | | Elizabeth Edwards |
| | | Chief Financial Officer |
